Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1/2
Tests MB-dNPM-1-TCR.1 in adults with relapsed or refractory acute myeloid leukemia
Tests MB-dNPM-1-TCR.1 in adults whose acute myeloid leukemia returned or did not respond.
Key facts
- Who runs it
- Miltenyi Biomedicine GmbH
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML.
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 32 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 31 Mar 2032
- Type of study
- Interventional
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia (AML) that has come back or has not responded to treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia that has relapsed or is refractory (did not respond to treatment).
Where in Netherlands
- Academisch Ziekenhuis LeidenLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests MB-dNPM-1-TCR.1 in adults with relapsed or refractory acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 March 2026